| Catalog No. |
TD-HV212036 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Isotype |
Fusion - [TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BR3, B cell activating factor receptor, CD268)]2 - IGHG1 Fc (Fragment constant) |
| Expression system |
Mammalian Cells |
| Target |
BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
Q9Y275 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
BR3-Fc,SS-79,CAS:869881-54-9 |
| Background |
Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA). |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |
抗体
试剂盒
多肽
探针
蛋白
组织芯片
定制服务咨询